Search results
Results From The WOW.Com Content Network
(Reuters) -Culper Research has taken a short position on Acadia Pharmaceuticals' stock, it said on Thursday, sending the drugmaker's shares down as much as 8%. Acadia's drug, trofinetide, to treat ...
Shares of the California-based company fell 16% in extended trading. The decision comes after two failed attempts to secure regulatory approval for the expanded use of pimavanserin in the ...
For premium support please call: 800-290-4726 more ways to reach us
Total equity. US$699.14 million (2019) Number of employees. 570 (June 30, 2020) Website. acadia .com. Footnotes / references. [1] Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California.
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year ... including $230,000 in stock-based compensation, from $4.4 million for the comparable quarter of 2011, including ...
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail ...
Acadia (ACAD) delivered earnings and revenue surprises of 5.56% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals Inc. (ACAD) has announced that it has filed a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential new indication ...